The projected effect of risk factor reduction on Alzheimer's disease prevalence - PubMed (original) (raw)

Review

The projected effect of risk factor reduction on Alzheimer's disease prevalence

Deborah E Barnes et al. Lancet Neurol. 2011 Sep.

Abstract

At present, about 33·9 million people worldwide have Alzheimer's disease (AD), and prevalence is expected to triple over the next 40 years. The aim of this Review was to summarise the evidence regarding seven potentially modifiable risk factors for AD: diabetes, midlife hypertension, midlife obesity, smoking, depression, cognitive inactivity or low educational attainment, and physical inactivity. Additionally, we projected the effect of risk factor reduction on AD prevalence by calculating population attributable risks (the percent of cases attributable to a given factor) and the number of AD cases that might be prevented by risk factor reductions of 10% and 25% worldwide and in the USA. Together, up to half of AD cases worldwide (17·2 million) and in the USA (2·9 million) are potentially attributable to these factors. A 10-25% reduction in all seven risk factors could potentially prevent as many as 1·1-3·0 million AD cases worldwide and 184,000-492,000 cases in the USA.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1

The number of Alzheimer's disease (AD) cases that could potentially be prevented through risk factor reductions of 10% or 25% worldwide (Figure 1a) and in the US (Figure 1b) was estimated by multiplying current prevalence estimates by 0.90 and 0.75, respectively, and subtracting the revised number of attributable cases from the original number. These estimates assume that a causal relationship exists between the risk factor and AD and that the relative risk estimate is a good approximation of the impact of risk factor reduction. Therefore, the actual number of cases prevented could be higher or lower depending on the extent to which these assumptions are valid. In addition, the combined estimate assumes that the individual risk factors are independent and have an additive relationship. Because several of the risk factors examined are inter-related, the combined PAR estimates should be considered as maximums.

Figure 2

Figure 2

Comment in

Similar articles

Cited by

References

    1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186–91. - PubMed
    1. [Accessed January 10, 2011];2010 Alzheimer's Disease Facts & Figures. 2010 at http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf.
    1. O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2010 [Epub ahead of print] - PubMed
    1. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557–64. - PMC - PubMed
    1. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304:1903–11. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources